Skip to Content
  • Aggregator Aggravation, In a New Way

    Experienced drug discovery folks, particularly those that work early on in the process, will tell you that aggregation is one of the most common sources of fals… Read More
  • Marathon’s Real Costs

    Endpoints has done a great breakdown on the actual costs that Marathon Pharmaceuticals is likely to have incurred while bringing their wildly overpriced old gen… Read More
  • A Call For Academic Drug Companies

    An editorial in Cell asks “How Much Longer Will We Put Up With $100,000 Cancer Drugs?” I’m of two minds on questions like that. OK, three mind… Read More
  • The Hollywood Analogy

    Yesterday’s drug-research-is-hard screed brought a lot of responses, and I wanted to address some particular points that came up. On Twitter, Alex Tabarro… Read More
  • Curcumin Will Waste Your Time

    I really enjoyed reading this article in J. Med. Chem. on curcumin. (Update: here’s the take over at Practical Fragments). That’s a well-known natur… Read More
  • Vivek Ramaswamy’s Plans

    I last wrote about Vivek Ramaswamy in the context of his first company (Axovant). That one went public on the hopes for a retread Alzheimer’s drug to wor… Read More
  • Not Fun Reading

    These numbers from Deloitte are not very reassuring. They do an annual survey of spending and returns on investment in the drug industry, and this year’s… Read More
Page 1 of 5212345...102030...Last »